MSI-H Cancer clinical trials at UCSF

1 research study open to eligible people

MSI-H cancer is a form of cancer with numerous DNA mutations. UCSF is conducting a study on an IL-2 immunotherapy to evaluate its safety and tumor-fighting potential. The trial is in its early phases and involves multiple research centers.

Showing trials for

  • Beta-only IL-2 ImmunoTherapY Study

    open to eligible people ages 18 years and up

    This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a checkpoint inhibitor in patients with advanced solid tumors.

    San Francisco, California and other locations

Last updated: